Ob/Gyn Medical News about ovarian cancer;mucinous

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pignata S et al. – Platinum-sensitive mucinous ovarian cancer has a poor response to chemotherapy; studies of this histological subgroup are needed

Methods

Retrospective study of chemotherapy activity in pts with platinum-sensitive recurrent mucinous ovarian cancer
Eligible pts had recurrent ovarian cancer with >6 mo platinum-free interval
Review of 20 pts with mucinous histotype and 388 pts with other histotypes

Results

At baseline, mucinous tumors differed from other tumors for an higher number of pts with lower tumor grading and less advanced FIGO stage
At recurrence, performance status was worse in mucinous pts (statistically significant difference)
Secondary cytoreduction for ~ 20% of pts in both groups; fewer pts optimally debulked in the mucinous group
As second line therapy, single-agent platinum vs platinum based-combination therapy or other non-platinum schedules were more frequent for mucinous cancer pts; also response rate was lower than in non-mucinous pts
Median time to progression and overall survival: worse for mucinous ovarian cancer
Mucinous cancer pts received fewer chemotherapy lines